Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.2 USD | -4.55% | -.--% | -.--% |
04-25 | Hangzhou Tigermed Consulting’s Profit Down 59% in Q1 | MT |
04-25 | Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the First Quarter Ended March 30, 2024 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's enterprise value to sales, at 4.89 times its current sales, is high.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-.--% | 6.03B | - | ||
+43.36% | 54.63B | B- | ||
-5.31% | 39.92B | B | ||
+14.75% | 26.86B | B- | ||
-12.56% | 26.22B | C | ||
-22.45% | 18.78B | B | ||
+25.12% | 12.21B | B+ | ||
+0.04% | 12.16B | B+ | ||
+26.04% | 11.94B | C+ | ||
-11.83% | 10.74B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 300347 Stock
- HNGZY Stock
- Ratings Hangzhou Tigermed Consulting Co., Ltd